Anti-Ki67 Antibody [PSH0-02]

HUABIO

Anti-Ki67 Antibody [PSH0-02]

2

Flow Cytometry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

PSH0-02

1 mg/ml

Unconjugated

MKI67

marker of proliferation Ki-67

KIA, MIB-, MIB-1, PPP1R105, proliferation marker protein Ki-67, Molecular Immunology Borstel antibody 1, antigen Ki67, antigen identified by monoclonal antibody Ki-67, proliferation-related Ki-67 antigen, protein phosphatase 1, regulatory subunit 105

Rabbit

IgG

Proliferation marker protein Ki-67

Antigen KI-67, also known as Ki-67, Ki-67 or MKI67 (Marker Of Proliferation Ki-67), is a protein that in humans is encoded by the MKI67 gene (antigen identified by monoclonal antibody Ki-67). Antigen KI-67 is a nuclear protein that is associated with cellular proliferation. Altering Ki-67 expression levels did not significantly affect cell proliferation in vivo. Ki-67 mutant mice developed normally and cells lacking Ki-67 proliferated efficiently. Furthermore, it is associated with ribosomal RNA transcription. Inactivation of antigen KI-67 leads to inhibition of ribosomal RNA synthesis. The Ki-67 protein (also known as MKI67) is a cellular marker for proliferation, and can be used in immunohistochemistry. It is strictly associated with cell proliferation. During interphase, the Ki-67 antigen can be exclusively detected within the cell nucleus, whereas in mitosis most of the protein is relocated to the surface of the chromosomes. Ki-67 protein is present during all active phases of the cell cycle (G1, S, G2, and mitosis), but is absent in resting (quiescent) cells (G0). Cellular content of Ki-67 protein markedly increases during cell progression through S phase of the cell cycle. In breast cancer Ki67 identifies a high proliferative subset of patients with ER-positive breast cancer who derive greater benefit from adjuvant chemotherapy. Ki-67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 labeling index) is often correlated with the clinical course of cancer. The best-studied examples in this context are prostate, brain and breast carcinomas, as well as nephroblastoma and neuroendocrine tumors. For these types of tumors, the prognostic value for survival and tumor recurrence have repeatedly been proven in uni- and multivariate analysis.

-20°C,2°C to 8°C

41116161